Fluspirilene

drug

On this page

Also known as FluspirilenoImapMCN-JR-6218R 6218R-6218RedeptinSID11111163SID11112501SID11532937SID26753577SID26753578SID50106303SID85231040SID90341058SID56422781SID104171151SID50106304SID124880066SID144203693

Summary

Fluspirilene (CHEMBL46516) is an approved small molecule (ATC N05AG01) targeting HTR1A, HRH1, and HTR1D; indicated across 5 conditions including psychotic disorder and anxiety.

At a glance

Status: Approved (max clinical phase 4)
Modality: Small molecule
ATC class: N05AG01
Targets: 5 (HTR1A, HRH1, HTR1D…)
Indications: 5 conditions
Clinical trials: 3
Chemistry: 475.6 Da · C29H31F2N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL46516
Name	Fluspirilene
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3396
ATC	N05AG01
Molecular formula	C29H31F2N3O
Molecular weight	475.6
InChIKey	QOYHHIBFXOOADH-UHFFFAOYSA-N

SMILES: C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F

IUPAC name: 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one

Also known as: Fluspirilene, Fluspirileno, Imap, MCN-JR-6218, R 6218, R-6218, Redeptin, SID11111163, SID11112501, SID11532937, SID26753577, SID26753578

Patent coverage: 13,156 distinct patent families (41,239 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR1A	5-HT_1A receptor	Antagonist	7.2	0%	P08908
HRH1	H₁ receptor	Antagonist	7.9	0%	P35367
HTR1D	5-HT_1D receptor	Antagonist	6	0%	P28221
HTR1E	5-ht_1e receptor	Antagonist	5.6	0%	P28566
HTR2A	5-HT_2A receptor	Antagonist	8	0%	P28223

Broader ChEMBL bioactivity targets: 68 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Lethal(3)malignant brain tumor-like protein 1, Microtubule-associated protein tau, Ubiquitin carboxyl-terminal hydrolase 2, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, RecQ-like DNA helicase BLM, 4’-phosphopantetheinyl transferase ffp, Thrombopoietin, NPC intracellular cholesterol transporter 1, Geminin, Endonuclease 4, Ras-related protein Rab-9A, Peripheral myelin protein 22, Protein RecA, X-box-binding protein 1, Replicative DNA helicase DnaB, Vasopressin V2 receptor, 5-hydroxytryptamine receptor 2B.

Bioactivity

ChEMBL activities: 50 potent at pChembl ≥ 5 of 115 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	7.4	AC50	40	nM	CHEMBL_ACT_25117782
DRD2	7.37	AC50	43	nM	CHEMBL_ACT_25140268
HTR2A	7.23	AC50	59	nM	CHEMBL_ACT_25173594
DRD3	7	AC50	100	nM	CHEMBL_ACT_25193463
HTR2B	6.82	Ki	151.4	nM	CHEMBL_ACT_3555290
SLC6A4	6.49	AC50	323	nM	CHEMBL_ACT_25150275
OPRL1	6.3	Ki	500	nM	CHEMBL_ACT_2604033
ADRA2B	6.19	AC50	640	nM	CHEMBL_ACT_25143638
HRH1	6.07	AC50	850	nM	CHEMBL_ACT_25212447
ADRA2C	6	AC50	1000	nM	CHEMBL_ACT_25147813
LMNA	6	Potency	1000	nM	CHEMBL_ACT_3657412
P22002	5.97	AC50	1068	nM	CHEMBL_ACT_25119542
HTR2A	5.96	AC50	1100	nM	CHEMBL_ACT_25225114
HTR6	5.92	Ki	1188	nM	CHEMBL_ACT_12059580
GLRA1	5.92	EC50	1200	nM	CHEMBL_ACT_15241391
OPRM1	5.92	AC50	1200	nM	CHEMBL_ACT_25157403
OPRK1	5.83	AC50	1482	nM	CHEMBL_ACT_25129368
CYP2D6	5.8	Potency	1585	nM	CHEMBL_ACT_4949899
CYP2D6	5.8	AC50	1585	nM	CHEMBL_ACT_5987225
ADRA1A	5.77	AC50	1699	nM	CHEMBL_ACT_25137891
CACNA1C	5.75	AC50	1800	nM	CHEMBL_ACT_25159089
KCNH2	5.64	IC50	2300	nM	CHEMBL_ACT_1449654
SLC6A3	5.52	AC50	3000	nM	CHEMBL_ACT_25123889
ADORA3	5.4	AC50	3989	nM	CHEMBL_ACT_25134148
HTR2B	5.34	AC50	4600	nM	CHEMBL_ACT_25227464
GAA	5.3	Potency	5012	nM	CHEMBL_ACT_4981208
GAA	5.3	Potency	5012	nM	CHEMBL_ACT_5026263
SLC6A2	5.22	AC50	6000	nM	CHEMBL_ACT_25144939
MEN1	5.2	Potency	6310	nM	CHEMBL_ACT_4570626
CYP3A4	5.2	Potency	6310	nM	CHEMBL_ACT_4973822
CYP3A4	5.2	Potency	6310	nM	CHEMBL_ACT_5042848
CYP3A4	5.2	AC50	6310	nM	CHEMBL_ACT_6057718
MC3R	5.19	AC50	6500	nM	CHEMBL_ACT_25183336
OPRD1	5.17	AC50	6700	nM	CHEMBL_ACT_25154005
GHSR	5.15	AC50	7100	nM	CHEMBL_ACT_25172694
CYP2C19	5.1	Potency	7943	nM	CHEMBL_ACT_4016521
USP2	5.1	Potency	7943	nM	CHEMBL_ACT_4699949
NPSR1	5.1	Potency	7943	nM	CHEMBL_ACT_4909301
CYP2C19	5.1	AC50	7943	nM	CHEMBL_ACT_6004299
CHRM3	5.09	AC50	8100	nM	CHEMBL_ACT_25136627
MEN1	5.05	Potency	8912	nM	CHEMBL_ACT_4566864
P9WMR3	5.01	AC50	9694	nM	CHEMBL_ACT_6543846
ADRB2	5	AC50	10100	nM	CHEMBL_ACT_25122819
MLNR	5	AC50	9900	nM	CHEMBL_ACT_25189126
NFKB1	5	Potency	10000	nM	CHEMBL_ACT_3672061
MAPT	5	Potency	10000	nM	CHEMBL_ACT_3964071
NFKB1	5	Potency	10000	nM	CHEMBL_ACT_4585343
CYP2D6	5	Potency	10000	nM	CHEMBL_ACT_4994235
XBP1	5	IC50	10000	nM	CHEMBL_ACT_5514376
CYP2D6	5	AC50	10000	nM	CHEMBL_ACT_5988490

Target pathways

Aggregated over 5 target gene(s): HTR1A, HRH1, HTR1D, HTR1E, HTR2A.

Top Reactome pathways

10 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	4	HTR1A, HTR1D, HTR1E, HTR2A
Signaling by GPCR	4	HTR1A, HTR1D, HTR1E, HTR2A
Class A/1 (Rhodopsin-like receptors)	4	HTR1A, HTR1D, HTR1E, HTR2A
Amine ligand-binding receptors	4	HTR1A, HTR1D, HTR1E, HTR2A
Serotonin receptors	4	HTR1A, HTR1D, HTR1E, HTR2A
GPCR ligand binding	4	HTR1A, HTR1D, HTR1E, HTR2A
GPCR downstream signalling	3	HTR1D, HTR1E, HTR2A
G alpha (q) signalling events	2	HRH1, HTR2A
G alpha (i) signalling events	2	HTR1D, HTR1E
Histamine receptors	1	HRH1

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	5
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5
chemical synaptic transmission	5
signal transduction	5
adenylate cyclase-inhibiting serotonin receptor signaling pathway	3
adenylate cyclase-activating G protein-coupled receptor signaling pathway	3
serotonin receptor signaling pathway	2
positive regulation of cell population proliferation	2
regulation of behavior	2
G protein-coupled serotonin receptor signaling pathway	2
memory	2
positive regulation of vasoconstriction	2
phospholipase C-activating serotonin receptor signaling pathway	2
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	2
behavioral fear response	1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02307396	PHASE4	COMPLETED	Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT01437553	Not specified	COMPLETED	Imaging Whole Coronary Artery With Intravascular Ultrasound (Ivus) And Imap For Plaque Tissue Composition In Patients With Acute Myocardial Infarction

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

673 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR1E, HTR2A
IMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR1E, HTR2A
RISPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR1E, HTR2A
RIZATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR1E, HTR2A
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR1E, HTR2A
LYSERGIDE	ChEMBL	Phase 2	HRH1, HTR1A, HTR1D, HTR1E, HTR2A
ASENAPINE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1E, HTR2A
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1E, HTR2A
CYPROHEPTADINE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1E, HTR2A
ERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1D, HTR1E, HTR2A
METHYLERGONOVINE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1E, HTR2A
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1E, HTR2A
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1E, HTR2A
QUETIAPINE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1E, HTR2A
SUMATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1D, HTR1E, HTR2A
ZIPRASIDONE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1E, HTR2A
ZOLMITRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1D, HTR1E, HTR2A
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR2A
AZELASTINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1D, HTR1E, HTR2A
CARIPRAZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR2A
CINACALCET	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR2A
KETANSERIN	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR2A
MIANSERIN	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR2A
NEFAZODONE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR2A
SEROTONIN	ChEMBL + PubChem	Phase 3 (approved)	HTR1A, HTR1D, HTR1E, HTR2A
YOHIMBINE	ChEMBL + PubChem	Phase 3 (approved)	HTR1A, HTR1D, HTR1E, HTR2A
LATREPIRDINE	ChEMBL	Phase 3	HRH1, HTR1D, HTR1E, HTR2A
MEBUFOTENIN	ChEMBL	Phase 2	HTR1A, HTR1D, HTR1E, HTR2A
PENFLURIDOL	ChEMBL	Phase 2	HRH1, HTR1A, HTR1D, HTR2A
PSILOCIN	ChEMBL	Phase 2	HTR1A, HTR1D, HTR1E, HTR2A
RITANSERIN	ChEMBL	Phase 2	HRH1, HTR1A, HTR1E, HTR2A
SPIRAMIDE	ChEMBL	Phase 2	HRH1, HTR1A, HTR1D, HTR2A
ALMOTRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR2A
CANNABIDIOL	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1E, HTR2A
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR2A
Fidaxomicin	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR2A
NARATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1D, HTR1E
OLODATEROL	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1D, HTR2A
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR2A
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR2A
SORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1E, HTR2A
TAMSULOSIN	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR2A
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
AMOXAPINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
APOMORPHINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
AZATADINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
BENFLUOREX	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
BENPERIDOL	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
BROMPERIDOL	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
BUSPIRONE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
CABERGOLINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
CINNARIZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
CISAPRIDE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
CITALOPRAM	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
CLEMASTINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
DEXCHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
DIBENZEPIN	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
DOMPERIDONE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
DOXEPIN	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
DULOXETINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
EBASTINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
FROVATRIPTAN	ChEMBL	Phase 4 (approved)	HTR1A, HTR1D, HTR1E
HALOPERIDOL	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
ILOPERIDONE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
IPRINDOLE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
LORCASERIN	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
LOXAPINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
LURASIDONE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
MAPROTILINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
MEFLOQUINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
METHYSERGIDE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
MIRTAZAPINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
NAFTOPIDIL	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	HTR1A, HTR1D, HTR2A
OXYPERTINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PERGOLIDE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PERPHENAZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PHENOXYBENZAMINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PHENTOLAMINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PIMOZIDE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PIPERACETAZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PRENYLAMINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PROMAZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PROMETHAZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PROPIOMAZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
PYRILAMINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
QUINAGOLIDE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
ROPINIROLE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
ROTIGOTINE	ChEMBL	Phase 4 (approved)	HRH1, HTR1A, HTR2A
SALMETEROL	ChEMBL	Phase 4 (approved)	HTR1A, HTR1D, HTR2A

Genes: HTR1A, HRH1, HTR1D, HTR1E, HTR2A
Indicated for: psychotic disorder
In clinical trials for: anxiety, dementia, depressive disorder
Drugs: Dihydroergotamine, Imipramine, Risperidone, Rizatriptan, Brexpiprazole, Asenapine, Clozapine, Cyproheptadine, Ergotamine, Methylergonovine, Olanzapine, Pramipexole, Quetiapine, Sumatriptan, Ziprasidone, Zolmitriptan, Aripiprazole, Azelastine, Cariprazine, Cinacalcet, Ketanserin, Mianserin, Nefazodone, Serotonin, Yohimbine, Latrepirdine, Almotriptan, Cannabidiol, Desloratadine, Fidaxomicin, Naratriptan, Olodaterol, Paliperidone, Propoxyphene, Regorafenib, Sorafenib, Tamsulosin, Acetophenazine, Amitriptyline, Amoxapine, Apomorphine, Astemizole, Azatadine, Benfluorex, Benperidol, Bromperidol, Buspirone, Cabergoline, Candesartan Cilexetil, Chlorpromazine, Cinnarizine, Cisapride, Citalopram, Clemastine, Clomipramine, Cyclobenzaprine, Dexchlorpheniramine, Dibenzepin, Domperidone, Doxepin, Duloxetine, Ebastine, Fluphenazine, Frovatriptan, Haloperidol, Iloperidone, Iprindole, Lorcaserin, Loxapine, Lurasidone, Maprotiline, Mefloquine, Methysergide, Mirtazapine, Naftopidil, Nortriptyline, Oxymetazoline, Oxypertine, Pergolide, Perphenazine, Phenoxybenzamine, Phentolamine, Pimozide, Piperacetazine, Prenylamine, Prochlorperazine, Promazine, Promethazine, Propiomazine, Pyrilamine, Quinagolide, Ropinirole, Rotigotine, Salmeterol

Summary

Identifiers

Drug identity and classification

Targets

Targets

Bioactivity

Target pathways

Top Reactome pathways

Dominant GO biological processes

Indications & clinical

Indications

Clinical trials

Phase distribution

Top trials by phase / activity

Clinical evidence (CIViC)

Pharmacology

Pharmacogenomics

Related molecules

Related molecules

Related Atlas pages